Kevin Outterson is a lawyer, a professor of law and the N. Neal Pike Scholar in Health and Disability Law at Boston University (2014–present).^[1] He is also the founding executive director and principal investigator^[2] of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that supports companies^[3] developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections. CARB-X is funded by^[4] the United States, United Kingdom and German governments, Wellcome and the Bill & Melinda Gates Foundation. In 2022, CARB-X received a new commitment of funding^[5] from BARDA and Wellcome of up to $370 million. The G7 Health Ministers have cited CARB-X^[6] among the critical initiatives to support as the G7 governments renew their 2021 commitment to address the most dangerous drug-resistant infections.

Outterson's research focuses primarily on the law and economics of antibiotic resistance–including push and pull incentives–health law, intellectual property, and global access to medicine.^[7]

Outterson has testified before Congress, the World Health Organization (WHO), UK Parliamentary working groups, and for the District of Columbia, Massachusetts, Vermont, California and West Virginia state legislatures.^[8]

He is co-director of the health law program at Boston University School of Law (2007–present) and associate fellow at the Royal Institute of International Affairs at Chatham House,^[9] London (2014–present). He served on the Board of the American Society of Law, Medicine & Ethics, and serves as faculty editor to the American Journal of Law & Medicine (2007–present). He is past editor-in-chief of the Journal of Law, Medicine & Ethics (2010–2016).^[7]